Allergan PLC. (AGN) Given a $255.00 Price Target by UBS AG Analysts

UBS AG set a $255.00 price objective on Allergan PLC. (NYSE:AGN) in a report published on Tuesday, October 17th, 99wallstreet.com reports. The firm currently has a buy rating on the stock.

AGN has been the subject of a number of other research reports. Citigroup Inc. reaffirmed a buy rating and issued a $280.00 price target on shares of Allergan PLC. in a research note on Wednesday, September 20th. Piper Jaffray Companies set a $227.00 target price on Allergan PLC. and gave the stock a hold rating in a research note on Friday, October 6th. Royal Bank Of Canada reissued a buy rating and set a $285.00 target price on shares of Allergan PLC. in a research note on Wednesday, September 6th. Wells Fargo & Company set a $276.00 target price on Allergan PLC. and gave the stock a buy rating in a report on Friday, October 13th. Finally, Cowen and Company reissued an outperform rating and issued a $400.00 price target on shares of Allergan PLC. in a research report on Saturday, September 23rd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have issued a buy rating to the company’s stock. Allergan PLC. presently has an average rating of Hold and an average price target of $252.39.

Allergan PLC. (NYSE AGN) traded up 0.354% on Tuesday, reaching $176.955. 2,100,775 shares of the company’s stock traded hands. The firm has a market cap of $59.16 billion, a price-to-earnings ratio of 5.391 and a beta of 1.15. The stock’s 50 day moving average is $208.20 and its 200 day moving average is $229.12. Allergan PLC. has a 52-week low of $175.21 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $3.35 earnings per share. On average, equities research analysts predict that Allergan PLC. will post $16.21 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/27/allergan-plc-agn-given-a-255-00-price-target-at-ubs-ag.html.

Allergan PLC. announced that its board has approved a stock buyback program on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.59%. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.

A number of institutional investors have recently added to or reduced their stakes in the business. Waldron LP purchased a new position in shares of Allergan PLC. in the first quarter worth $348,000. HL Financial Services LLC raised its stake in shares of Allergan PLC. by 5.8% in the first quarter. HL Financial Services LLC now owns 27,243 shares of the company’s stock worth $6,509,000 after purchasing an additional 1,504 shares during the last quarter. Palladium Partners LLC raised its stake in shares of Allergan PLC. by 6.0% in the first quarter. Palladium Partners LLC now owns 30,638 shares of the company’s stock worth $7,320,000 after purchasing an additional 1,722 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Allergan PLC. by 246.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 113,582 shares of the company’s stock worth $27,137,000 after purchasing an additional 80,829 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. raised its stake in shares of Allergan PLC. by 11.0% in the first quarter. Neville Rodie & Shaw Inc. now owns 3,074 shares of the company’s stock worth $734,000 after purchasing an additional 305 shares during the last quarter. 82.04% of the stock is currently owned by institutional investors and hedge funds.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply